SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange approximately $139.2 million in aggregate principal amount of the notes for approximately 6.8 million shares of the Company's common stock. The notes represented approximately 43% of the previously outstanding principal amount of the notes.